Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
22 hedge funds and large institutions have $281K invested in Better Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
22% more funds holding
Funds holding: 18 → 22 (+4)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
70% less capital invested
Capital invested by funds: $931K → $281K (-$650K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$41.3K |
| 2 |
Millennium Management
New York
|
+$20K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.27K |
| 5 |
CIAS
Capital Investment Advisory Services
Raleigh,
North Carolina
|
+$6.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$267K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$65.6K |
| 3 |
NAS
NWF Advisory Services
Los Angeles,
California
|
-$5.66K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$1.81K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$92 |
BTTX Hedge Fund Activity: Q4 2023 in Review
22 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q4 2023, worth a combined $281K — down 70% from $931K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BTTX positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $41.3K. The largest seller was MMCAP International, cutting an estimated $267K.
- 22 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q4 2023, up from 18 in Q3 2023.
- Funds reported $281K of Better Therapeutics, Inc. Common Stock stock for Q4 2023, down 70% quarter-over-quarter.
- 6 funds opened new Better Therapeutics, Inc. Common Stock positions in Q4 2023 and 2 closed out, a net change of +4 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q4 2023 was Citadel Advisors, an estimated $41.3K added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q4 2023 was MMCAP International, an estimated $267K sold.
Based on aggregated 13F filings for Q4 2023.